Ameritas Investment Partners’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $39.8K | Hold |
1,472
| – | – | ﹤0.01% | 2230 |
|
|
2025
Q4 | $63K | Hold |
1,472
| – | – | ﹤0.01% | 1972 |
|
|
2025
Q3 | $41.7K | Sell |
1,472
-9
| -0.6% | -$269 | ﹤0.01% | 2279 |
|
|
2025
Q2 | $27.7K | Hold |
1,481
| – | – | ﹤0.01% | 2513 |
|
|
2025
Q1 | $26.6K | Hold |
1,481
| – | – | ﹤0.01% | 2424 |
|
|
2024
Q4 | $24.9K | Hold |
1,481
| – | – | ﹤0.01% | 2537 |
|
|
2024
Q3 | $24K | Hold |
1,481
| – | – | ﹤0.01% | 2559 |
|
|
2024
Q2 | $12.2K | Hold |
1,481
| – | – | ﹤0.01% | 2852 |
|
|
2024
Q1 | $21.9K | Hold |
1,481
| – | – | ﹤0.01% | 2533 |
|
|
2023
Q4 | $21.5K | Hold |
1,481
| – | – | ﹤0.01% | 2556 |
|
|
2023
Q3 | $16K | Hold |
1,481
| – | – | ﹤0.01% | 2640 |
|
|
2023
Q2 | $19.1K | Hold |
1,481
| – | – | ﹤0.01% | 2586 |
|
|
2023
Q1 | $19.5K | Hold |
1,481
| – | – | ﹤0.01% | 2479 |
|
|
2022
Q4 | $27.1K | Hold |
1,481
| – | – | ﹤0.01% | 2420 |
|
|
2022
Q3 | $17K | Hold |
1,481
| – | – | ﹤0.01% | 2604 |
|
|
2022
Q2 | $16K | Hold |
1,481
| – | – | ﹤0.01% | 2661 |
|
|
2022
Q1 | $44K | Hold |
1,481
| – | – | ﹤0.01% | 2131 |
|
|
2021
Q4 | $39K | Hold |
1,481
| – | – | ﹤0.01% | 2295 |
|
|
2021
Q3 | $54K | Hold |
1,481
| – | – | ﹤0.01% | 2106 |
|
|
2021
Q2 | $64K | Hold |
1,481
| – | – | ﹤0.01% | 2023 |
|
|
2021
Q1 | $51K | Hold |
1,481
| – | – | ﹤0.01% | 2077 |
|
|
2020
Q4 | $52K | Hold |
1,481
| – | – | ﹤0.01% | 1974 |
|
|
2020
Q3 | $36K | Buy |
1,481
+220
| +17% | +$5.4K | ﹤0.01% | 2038 |
|
|
2020
Q2 | $23K | Hold |
1,261
| – | – | ﹤0.01% | 2298 |
|
|
2020
Q1 | $20K | Hold |
1,261
| – | – | ﹤0.01% | 2189 |
|
|
2019
Q4 | $27K | Hold |
1,261
| – | – | ﹤0.01% | 2264 |
|
|
2019
Q3 | $24K | Hold |
1,261
| – | – | ﹤0.01% | 2297 |
|
|
2019
Q2 | $33K | Hold |
1,261
| – | – | ﹤0.01% | 2151 |
|
|
2019
Q1 | $32K | Hold |
1,261
| – | – | ﹤0.01% | 2120 |
|
|
2018
Q4 | $29K | Hold |
1,261
| – | – | ﹤0.01% | 2118 |
|
|
2018
Q3 | $40K | Hold |
1,261
| – | – | ﹤0.01% | 2118 |
|
|
2018
Q2 | $36K | Hold |
1,261
| – | – | ﹤0.01% | 2193 |
|
|
2018
Q1 | $45K | Buy |
1,261
+222
| +21% | +$8.89K | ﹤0.01% | 1974 |
|
|
2017
Q4 | $40K | Hold |
1,039
| – | – | ﹤0.01% | 2046 |
|
|
2017
Q3 | $26K | Hold |
1,039
| – | – | ﹤0.01% | 2285 |
|
|
2017
Q2 | $28K | Buy |
1,039
+280
| +37% | +$7.66K | ﹤0.01% | 2267 |
|
|
2017
Q1 | $25K | Buy |
+759
| New | +$19.3K | ﹤0.01% | 2286 |
|
Other funds holding RIGL
AC
VCM
Ameritas Investment Partners's RIGL Position: Q1 2026 in Review
Ameritas Investment Partners held its Rigel Pharmaceuticals (RIGL) position steady in Q1 2026 at 1,472 shares worth $39.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2230.
Ameritas Investment Partners first reported a position in RIGL in Q1 2017 and has held it in 37 quarters since. The position peaked at $64K in Q2 2021. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.
- Ameritas Investment Partners held 1,472 shares of Rigel Pharmaceuticals worth $39.8K as of Q1 2026.
- Ameritas Investment Partners left its Rigel Pharmaceuticals share count unchanged in Q1 2026.
- Rigel Pharmaceuticals made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #2230 holding.
- Ameritas Investment Partners first reported a position in Rigel Pharmaceuticals in Q1 2017 and has held it in 37 quarters since.
- Ameritas Investment Partners's Rigel Pharmaceuticals position peaked at $64K in Q2 2021.
- 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.
Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.